BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 8 Most Promising Biotech Stocks to Buy Now. On May 8, Evercore ISI raised ...
BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby ...
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the stocks with explosive growth potential. On February 24, BridgeBio Pharma reported a transformative full-year 2025, marked by a surge in total revenue ...
Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDTCompany ParticipantsThomas Trimarchi - CFO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results